Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PTPTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT)

NASDAQ Global Select · Currency in USD
$60.59 ▼ -2.45 (-3.89%)
At close: Oct 23, 4:00 PM ET. Market closed.
$60.59 ▲ +0.00 (+0.00%)
After hours: Oct 23, 5:09 PM ET

Summary

Previous Close
$63.04
Open
$62.30
Day's Range
$59.97 – $62.90
52 Week Range
$58.80 – $90.87
Volume
674,206
Avg. Volume
1,401,179
Market Cap
$5.06B
Beta (5Y Monthly)
0.55
PE Ratio (TTM)
--
EPS (TTM)
-$0.46
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$102.89

Profile: PTC Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
991
CEO
Matthew Klein
Website
ptcbio.com

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $0.21 · Revenue est. $304.60M
DateEst.Actual
Jul 30, 2026$0.24$0.92Beat
May 7, 2026-$0.45-$0.03Beat
Feb 19, 2026-$0.21-$1.67Miss
Nov 4, 2025-$1.19$0.20Beat
Aug 7, 2025-$1.07-$0.83Beat
May 6, 2025-$1.08$10.04Beat

Analyst view

Consensus price target
$102.89 ▲ +69.8%
Range $75.00 – $137.00
Rating: Buy
Buy 65% · Hold 27% · Sell 8%

Get free alerts on PTCT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.